Endometriosis patients report health-related quality of life improvements following the use of medical cannabis preparations, according to observational data published in the journal Obstetrics & Gynaecology.
British investigators assessed the use of cannabis-based medicinal products (CBMPs) in a cohort of 63 endometriosis patients enrolled in the UK Medical Cannabis Registry. Patients’ outcomes were assessed at baseline and at one, three, six, twelve and eighteen months. Study participants consumed either herbal cannabis or oil extracts containing a nearly equal ratio of THC and CBD.
Patients acknowledged improvements in their chronic pain and other health-related quality of life measures following cannabis therapy.
“These results provide a signal towards improvement in short-term pain severity and interference for endometriosis patients after the initiation of CMBP treatment”, the study’s authors concluded. “This study provides valuable real-world data and complements the development of RCTs [randomised clinical trials] to further examine the efficacy and safety of CBMPs for endometriosis-associated chronic pain”.
12 December, 2025